Online inquiry

IVTScrip™ mRNA-Human ARHGEF39, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK28619MR)

This product GTTS-WK28619MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF39 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_032818.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 84904
UniProt ID Q8N4T4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF39, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK28619MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK14043MR IVTScrip™ mRNA-Human ADGRG5, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADGRG5
GTTS-WK22375MR IVTScrip™ mRNA-Human ARRB1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARRB1
GTTS-WK14935MR IVTScrip™ mRNA-Human ANKRD66, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANKRD66
GTTS-WK25005MR IVTScrip™ mRNA-Human ARHGDIB, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGDIB
GTTS-WK5093MR IVTScrip™ mRNA-Human GPR44, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GPR44
GTTS-WK9491MR IVTScrip™ mRNA-Human ADAM17, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADAM17
GTTS-WK27709MR IVTScrip™ mRNA-Human ARHGEF12, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARHGEF12
GTTS-WK8608MR IVTScrip™ mRNA-Human ADAMTSL1, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADAMTSL1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW